CTOR

Citius Oncology Inc

0.7756

Aug 28 • 3:59 PM ET -0.0147 (-1.86%)

0.7756

Aftermarket • 4:15 PM ET 0.0000 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD

Peers: SCLX AMRN DERM CRDL LFCR ADCT ANIK TKNO EBS HROW

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	72.11M
Enterprise Value	65.76M
Income	-46.06M
Sales	7.11M
Book/sh	0.38
Cash/sh	0.18
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Dec 08, 2022

P/E	-
Forward P/E	7.76
PEG	-
P/S	10.14
P/B	2.03
P/C	4.35
P/FCF	-
EV/EBITDA	-
EV/Sales	9.25
Quick Ratio	0.34
Current Ratio	0.73
Debt/Eq	0.25
LT Debt/Eq	0.25
Option/Short	No / Yes

EPS (ttm)	-0.47
EPS next Y	0.10
EPS next Q	-0.19
EPS this Y	-64.71%
EPS next Y	117.86%
EPS next 5Y	-
EPS past 3/5Y	- -309.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	-148.79%
Sales Y/Y TTM	-
EPS Q/Q	-10.27%
Sales Q/Q	-
Earnings	Aug 14 AMC
EPS/Sales Surpr.	-14.29% -40.25%

Insider Own	71.95%
Insider Trans	0.00%
Inst Own	15.21%
Inst Trans	0.41%
ROA	-45.20%
ROE	-126.58%
ROIC	-91.04%
Gross Margin	28.92%
Oper. Margin	-665.63%
Profit Margin	-648.32%
SMA20	1.98%
SMA50	12.10%
SMA200	-14.68%
Trades

Shs Outstand	105.76M
Shs Float	26.09M
Short Float	1.73%
Short Ratio	5.48
Short Interest	0.45M
52W High	2.25 -65.53%
52W Low	0.49 57.90%
Volatility	8.02% 11.38%
ATR (14)	0.08
RSI (14)	54.40
Beta	3.56
Rel Volume	0.26
Avg Volume	82.61K
Volume	21,705

Perf Week	4.28%
Perf Month	35.17%
Perf Quarter	-2.81%
Perf Half Y	-30.75%
Perf YTD	-22.44%
Perf Year	-63.42%
Perf 3Y	-92.79%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	4.00
Prev Close	0.79
Price	0.78
Change %	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy	$6
Nov-27-24	Initiated	Maxim Group	Buy	$3

Aug-17-26 08:28AM	Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum (InvestorsHub) -18.66%
Aug-14-26 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire) +10.04%
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Aug-12-26 08:00AM	Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri (PR Newswire) +11.16%
Aug-05-26 09:17AM	Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment (PR Newswire) +18.94%
09:17AM	Loading…
Jul-21-26 09:17AM	Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption (PR Newswire)
Jun-01-26 07:00AM	Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies (PR Newswire)
May-26-26 08:00AM	Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting (PR Newswire)
May-15-26 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -13.95%
04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
May-06-26 09:04AM	Citius raises $36.5m for Lymphir commercialisation (Pharmaceutical Technology)
May-05-26 08:00PM	Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization (PR Newswire)
Apr-29-26 08:00AM	Citius Oncology Ships First International Order of LYMPHIR to Europe (PR Newswire)
Mar-31-26 09:11AM	Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development (PR Newswire) +25.74%
Mar-24-26 08:00AM	Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts (PR Newswire) -6.83%
08:47AM	Loading…
Mar-10-26 08:47AM	Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers (PR Newswire)
Mar-04-26 09:15AM	Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma (PR Newswire)
Feb-24-26 09:35AM	Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar (Insider Monkey)
Feb-13-26 08:00AM	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
08:00AM	Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
Feb-12-26 06:55AM	Citius Oncology and Uniphar sign European distribution deal for Lymphir (Pharmaceutical Business Review)
Feb-11-26 08:00AM	Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar (PR Newswire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
Dec-23-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -9.84%
Dec-10-25 04:30PM	Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +6.42%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) -9.02%
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) +19.71%
Nov-25-25 08:00AM	Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting (PR Newswire) +8.04%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire)
08:19AM	Loading…
Oct-21-25 08:19AM	Citius Oncology finalises McKesson deal for Lymphir distribution (Pharmaceutical Business Review)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +5.29%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire) -5.03%
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 08:47AM	Citius Oncology Establishes International Access to LYMPHIR via Named Patient Programs in Southern Europe (PR Newswire)
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +7.36%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +5.92%
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +5.52%
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire) -20.62%
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire) +26.81%
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +17.13%
May-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Feb-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -5.60%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire) -5.56%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) -11.69%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire) +18.46%
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +8.33% +7.69%
05:00PM	Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

CEOMr. Leonard L. Mazur

Secretary & Executive Vice ChairmanMr. Myron Z. Holubiak

Executive VP & Chief Medical OfficerDr. Myron S. Czuczman M.D.

Chief Financial Officer & TreasurerMr. Jaime Bartushak

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your Finviz experience